Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- Garlic4Independent statistical analysis of Effect of Aged Garlic Extract on Atherosclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01534910).
- GARMIndependent statistical analysis of Multifocal Contact Lens Use in Previous Contact Lens Wearers With Near Vision Demands: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Gastric Ultrasound in Tube Fed Intubated Patients: Complete Statistical AnalysisIndependent statistical analysis of Gastric Ultrasound in Tube Fed Intubated Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04612348).
- Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus: Complete Statistical AnalysisIndependent statistical analysis of Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02170870).
- GATEWAYIndependent statistical analysis of A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GAVOTTEIndependent statistical analysis of A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS): primary endpoint results, effect…
- GB001 in Adult Participants With Chronic Rhinosinusitis: Complete Statistical AnalysisIndependent statistical analysis of GB001 in Adult Participants With Chronic Rhinosinusitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03956862).
- GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD): Complete Statistical AnalysisIndependent statistical analysis of GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GDCTIndependent statistical analysis of Somatropin Treatment to Final Height in Turner Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00191113).
- GDX-44-016Independent statistical analysis of Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06057168).
- Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery: primary endpoint results, effect estimate with confidence interval,…
- Gel-One Treatment in Knee Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of Gel-One Treatment in Knee Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01934218).
- Gemcabene for the Treatment of Pediatric NAFLD: Complete Statistical AnalysisIndependent statistical analysis of Gemcabene for the Treatment of Pediatric NAFLD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03436420).
- Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00388154).
- Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval,…
- Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval,…
- Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer…
- Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01938716).
- Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- GEMINIIndependent statistical analysis of A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- GEMINI IIIndependent statistical analysis of Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GEMINI Study – A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection: Complete Statistical AnalysisIndependent statistical analysis of GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Gemzar, Cisp, Sunitinib Urothelial Ca: Complete Statistical AnalysisIndependent statistical analysis of Gemzar, Cisp, Sunitinib Urothelial Ca: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00821327).
- GEN206Independent statistical analysis of Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00677924).
- Gene Signatures of Influenza Vaccine Responses in Older Adults: Complete Statistical AnalysisIndependent statistical analysis of Gene Signatures of Influenza Vaccine Responses in Older Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03603509).
- Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1: Complete Statistical AnalysisIndependent statistical analysis of Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02122952).
- Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD: Complete Statistical AnalysisIndependent statistical analysis of Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- GENEr8-2Independent statistical analysis of Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg: primary endpoint results, effect estimate with confidence…
- GENEr8-AAV5+Independent statistical analysis of Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- General Anesthesia With ETT vs LMA in Patients Undergoing Ablation for Atrial Fibrillation: Complete Statistical AnalysisIndependent statistical analysis of General Anesthesia With ETT vs LMA in Patients Undergoing Ablation for Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- GENERATIONIndependent statistical analysis of Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Genetic Basis for Variation in the Renal Elimination of Metformin: Complete Statistical AnalysisIndependent statistical analysis of Genetic Basis for Variation in the Renal Elimination of Metformin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00187720).
- Genetic Effects on Dopamine Response to an Opiate: Complete Statistical AnalysisIndependent statistical analysis of Genetic Effects on Dopamine Response to an Opiate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01878006).
- Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes: Complete Statistical AnalysisIndependent statistical analysis of Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00108303).
- Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation: Complete Statistical AnalysisIndependent statistical analysis of Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas: Complete Statistical AnalysisIndependent statistical analysis of Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma: Complete Statistical AnalysisIndependent statistical analysis of Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream: Complete Statistical AnalysisIndependent statistical analysis of Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…